Urokinase-type plasminogen activator, an endogenous antibiotic

Prior research has shown that urokinase-type plasminogen activator (uPA) is a serine protease involved in fibrinolysis and immune modulation. However, its role in direct bacterial inhibition remains unclear. Established knowledge includes uPA's involvement in immune response pathways but not its potential as an endogenous antibiotic. This gap motivated an investigation into whether uPA can inhibit bacterial growth. No prior work had resolved the mechanism of uPA's antibacterial effects. Existing studies focus on plasminogen activation rather than direct microbial inhibition. This paper's contribution is to explore uPA's antibacterial function in both in vitro and in vivo settings. The study addresses the uncertainty of uPA's role in host defense against bacterial infections. The findings may expand the known functions of uPA beyond fibrinolysis and immune modulation.

The aim of this study was to assess whether urokinase-type plasminogen activator (uPA) functions as an endogenous antibiotic. The specific problem addressed is the lack of clarity regarding uPA's direct antibacterial activity. The motivation stems from prior observations of uPA's immune-modulating properties and its potential role in host defense. The researchers propose to test uPA's effect on Staphylococcus aureus growth in both in vitro and in vivo models. The study seeks to determine if uPA's antibacterial activity is independent of its plasminogen-activation function. The researchers also aim to evaluate changes in uPA and PAI-1 levels during infection. The study focuses on the relationship between active uPA levels and bacterial load in infected tissues. The findings may clarify uPA's role in innate immunity against bacterial infections.

The researchers used in vitro and in vivo models to assess uPA's antibacterial activity. Staphylococcus aureus was cultured in the presence of uPA to evaluate growth inhibition. Murine models of staphylococcal sepsis were used to observe the effects of uPA treatment. Plasma and kidney homogenates were collected to measure total and active uPA levels. PAI-1 levels were quantified in the same samples to assess regulatory interactions. The study employed Western blotting to detect active uPA and ELISA for PAI-1 quantification. Bacterial load in kidney homogenates was measured to correlate with uPA levels. The researchers analyzed the inverse relationship between active uPA and PAI-1 levels during infection.

Urokinase-type plasminogen activator (uPA) inhibited Staphylococcus aureus growth in both in vitro and in vivo models. The antibacterial effect was linked to the serine protease domain of uPA. The activity was independent of uPA's plasminogen-activation function. In murine sepsis models, uPA treatment reduced bacterial load and improved survival. Total uPA levels remained constant in plasma and kidney homogenates. Active uPA levels decreased in kidney homogenates but not in plasma. PAI-1 levels increased significantly in plasma and kidney homogenates during infection. Active uPA levels were inversely correlated with PAI-1 levels and bacterial load in infected tissues.

The authors report that uPA functions as an endogenous antibacterial substance against Staphylococcus aureus. The antibacterial activity is attributed to the serine protease domain of uPA. The effect is independent of plasminogen-activation function and not inhibited by PAI-1. The study suggests uPA may be part of the first line of host defense against staphylococcal infection. The decrease in active uPA in infected organs is linked to increased PAI-1 production. The findings highlight a potential regulatory mechanism in host defense against bacterial infections. The inverse relationship between active uPA and bacterial load supports a protective role for uPA. The study provides evidence for uPA's direct antibacterial function in addition to its known roles.